<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5FA451D-4FA7-423E-93F8-046141371F35"><gtr:id>D5FA451D-4FA7-423E-93F8-046141371F35</gtr:id><gtr:name>University of Western Australia</gtr:name><gtr:address><gtr:line1>35 Stirling Highway</gtr:line1><gtr:line4>Crawley</gtr:line4><gtr:line5>WA 6009</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5FA451D-4FA7-423E-93F8-046141371F35"><gtr:id>D5FA451D-4FA7-423E-93F8-046141371F35</gtr:id><gtr:name>University of Western Australia</gtr:name><gtr:address><gtr:line1>35 Stirling Highway</gtr:line1><gtr:line4>Crawley</gtr:line4><gtr:line5>WA 6009</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89DF462-9EA4-4042-B006-DC19F73B5B9E"><gtr:id>E89DF462-9EA4-4042-B006-DC19F73B5B9E</gtr:id><gtr:firstName>Beate</gtr:firstName><gtr:surname>Kampmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DF45180A-FF55-4FCA-84FB-B2DB24B7A222"><gtr:id>DF45180A-FF55-4FCA-84FB-B2DB24B7A222</gtr:id><gtr:firstName>Umberto</gtr:firstName><gtr:surname>D'Alessandro</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BB8CCC4E-498D-4876-8064-A5AD57294642"><gtr:id>BB8CCC4E-498D-4876-8064-A5AD57294642</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>L</gtr:otherNames><gtr:surname>Bailey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C166EF2D-FBDF-4D1F-A789-7379B587FF9C"><gtr:id>C166EF2D-FBDF-4D1F-A789-7379B587FF9C</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Antonio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A7FD67D-7A17-456A-B658-59679012F340"><gtr:id>4A7FD67D-7A17-456A-B658-59679012F340</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Roca</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_EX_MR%2FJ010391%2F1"><gtr:id>FDBC2837-291A-4D63-9F37-20EFEAD0E0F7</gtr:id><gtr:title>Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_MR/J010391/1</gtr:grantReference><gtr:abstractText>The last decade has witnessed an important reduction of the mortality in children less than 5 years of age. Nevertheless, such reduction occurred mainly in children older than 1 month; no change was observed in newborns (between birth and one month of age). Mortality in this age group contributes half of all deaths occurring in children below 5 years of age. Sixteen out of the 20 countries with the highest neonatal mortality are in sub-Saharan Africa. In 1990, the United Nations established the Millennium Development Goals (MDG) aiming at improving by 2015 living conditions of the poorest populations. The MDG number 4 aims at reducing by two-thirds the under-five mortality, a result attainable only with a substantial reduction in neonatal deaths.</gtr:abstractText><gtr:technicalSummary>Millennium Development Goal number 4 (MDG-4) identifies decreasing childhood mortality as a priority area for international development. Despite important reduction in under-five mortality observed in some countries, neonatal mortality has remained stable, with consequent increase in the proportion of neonatal deaths (40%) among all under five fatalities. MDG-4 is unlikely to be achieved without substantial reduction in neonatal mortality.
Sepsis is a leading cause of neonatal deaths in developing countries, mainly in sub-Saharan Africa (SSA). Neonatal sepsis is a consequence of early bacterial infection. These infections are often transmitted by the mother to the newborn, either intrapartum (vaginal canal) or during the first days of life (nasopharyngeal carriage) when the close physical contact between her and the newborn expose the latter to the risk of being infected. 
In SSA, additional benefits of mass-campaigns administering one oral dose of azithromycin (AZI) for trachoma control include lower nasopharyngeal bacterial carriage and lower childhood mortality. AZI is a broad spectrum antibiotic that covers a wide range of bacteria and is suitable for being used in SSA. Though AZI is defined by the Food and Drug Administration as a pregnancy category B drug, extensive published data of randomized clinical trials show no harm for both pregnant women and newborns.
The objective of the study is to evaluate the impact of one dose of AZI given during labour on bacterial carriage of the newborn and the mother. The underlying hypothesis is that this intervention can decrease bacterial carriage both in the mother and the newborn and consequently the risk of invasive bacterial disease in the newborn. Our proof-of-concept - Phase III-b randomized clinical trial - will be conducted in a rural health facility in Gambia. If successful, next step will be a larger study evaluating the same intervention given at the lowest level of care on the incidence of neonatal sepsis.</gtr:technicalSummary><gtr:potentialImpactText>Our study opens the opportunity to impact on the Millennium Development Goal number 4 of reducing childhood mortality by 2015, a current priority in Global Health. Such an impact on under-five mortality should occur on newborns, the most vulnerable age group, by preventing neonatal bacterial infections and most likely subsequently sepsis. Along with this, the study will expand the worldwide academic knowledge on the prevention of neonatal bacterial infections, subsequent sepsis and associated mortality, using innovate methodologies.

All participants recruited for the study (720 mother/newborn pairs - two groups at very high risk of morbidity and mortality) will benefit from the intervention during birth and the follow-up period (the first month of life) as a healthy effect of the intervention. The impact of such healthy effect is marked in populations where health personnel are scarce. In addition, if our study hypothesis proves correct, children born from treated mothers will have a lower risk of nasopharyngeal bacterial carriage and consequently of sepsis. 

This study will offer the opportunity for at least one PhD training fellowship (either a medical doctor to be trained in research methods of infectious diseases and global health or a laboratory-based scientist). Young West-African scientists will be preferentially selected, though the training opportunity will be open to any young researcher with the required expertise and working in an African context.

As any study conducted in a poor-resource setting, capacity building is an important component. Study staff at different levels will receive continuous training on several aspects related to clinical research such as Good Clinical Practices or Ethics. In addition, we will include specific training sessions for the field staff; laboratory technicians will be exposed, as part of the study, to a high-standard microbiological and scientific environment (WHO reference laboratory for microbiology), an almost unique opportunity in the African continent. 

The final aim of our trial is to transform the proposed intervention into policy to be implemented at any level of antenatal care in Africa, including delivering women assisted by traditional birth attendants, a common practice in rural Africa where health centres are not easily accessible for a substantial proportion of the population. The potential of a major impact on early neonatal mortality with a relatively simple intervention is high. Assuming favourable results, the intervention could save hundreds of thousands of lives.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Molecular analysis</gtr:description><gtr:id>6C8DA19B-B004-48C6-9E73-2EFFB5AB8B03</gtr:id><gtr:impact>PhD ongoing</gtr:impact><gtr:outcomeId>545ca6beb08274.62269187-1</gtr:outcomeId><gtr:partnerContribution>Molecular analysis and resistance mechanisms</gtr:partnerContribution><gtr:piContribution>Provide samples and epidemiological expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Western Australia</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Azithromycin measurement</gtr:description><gtr:id>0556B75F-8E5A-4E2E-AE12-0C4D3E993F25</gtr:id><gtr:impact>The work is ongoing</gtr:impact><gtr:outcomeId>Z3kFia4yq8q-1</gtr:outcomeId><gtr:partnerContribution>This laboratory is measuring concentration of azithromycin in the breast milk samples of 40 participants of the trial</gtr:partnerContribution><gtr:piContribution>We have provided the study hypotheses, study design, clinical information and samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Infectious and Tropical Diseases</gtr:department><gtr:description>Low birth weigth and bacterial infection in the vaginal tract</gtr:description><gtr:id>E8E1140B-FDDD-409A-8A65-26AB27B8491E</gtr:id><gtr:impact>The analysis needs yet to start.</gtr:impact><gtr:outcomeId>56dd8c2b39dd08.57920042-1</gtr:outcomeId><gtr:partnerContribution>Laboratory analysis</gtr:partnerContribution><gtr:piContribution>Add an additional research question to the study which is to assess maternal vaginal bacterial carriage as a risk factor for low birth weigth in the gambia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRCG Annual report</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8D7AC131-4DF8-432F-8E24-3687BC7C2942</gtr:id><gtr:impact>MRC Unit The Gambia annual report shows the results of the PregnAnZI trial and the future steps</gtr:impact><gtr:outcomeId>56dd89f22c4988.36359900</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TAMA - Unit The Gambia journal</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E9562C50-5FF8-4B20-B0FB-F07511E95607</gtr:id><gtr:impact>Description of the trial that the Unit was going to undertake and the importance of a trial targeting new-borns who concentrate a high burden of mortality in Africa

NA</gtr:impact><gtr:outcomeId>545ca816abf709.68786257</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N022149/1</gtr:fundingRef><gtr:id>FE81305A-7225-45F2-B52F-733092CBF4AA</gtr:id><gtr:outcomeId>58ca7226676249.12238082</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1D9720BC-B033-4BB0-8891-E9A51D04AC4B</gtr:id><gtr:title>Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>585d6e6076b7f4.88231447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3708A6BA-6BA1-4477-B251-9355F697B552</gtr:id><gtr:title>Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African Mothers.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b06c6fb91110f981ed0bd9ca02bf345"><gtr:id>3b06c6fb91110f981ed0bd9ca02bf345</gtr:id><gtr:otherNames>Salman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>56d94ac2c5d640.93133719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A41878-0ECC-48B8-9345-E41FBFC6BF4B</gtr:id><gtr:title>Maternal colonization with Staphylococcus aureus and Group B streptococcus is associated with colonization in newborns.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>5a93ef9392e623.07777638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF14D852-9239-47E1-9956-39D0974B86BF</gtr:id><gtr:title>Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: Study protocol of a randomized efficacy trial.</gtr:title><gtr:parentPublicationTitle>BMC pregnancy and childbirth</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2393</gtr:issn><gtr:outcomeId>56d94b0336ce85.61455483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0681CF3B-3F27-461E-A115-24239283D5B7</gtr:id><gtr:title>Does azithromycin given to women in labour decrease ocular bacterial infection in neonates? A double-blind, randomized trial.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db43f348aaf5d9c0f1ba4ee19da6796d"><gtr:id>db43f348aaf5d9c0f1ba4ee19da6796d</gtr:id><gtr:otherNames>Burr SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>5a93eccc7862c3.37243928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BD9A916-5D33-4076-8EBA-27223A1FB392</gtr:id><gtr:title>Azithromycin in Labor Lowers Clinical Infections in Mothers and Newborns: A Double-Blind Trial.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09d65a9f2d3d277704045dd877dc92a0"><gtr:id>09d65a9f2d3d277704045dd877dc92a0</gtr:id><gtr:otherNames>Oluwalana C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>5898858e649959.04484680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6257573-685D-43E1-AF6E-3D4DCD00F319</gtr:id><gtr:title>Maternal pneumococcal nasopharyngeal carriage and risk factors for neonatal carriage after the introduction of pneumococcal conjugate vaccines in The Gambia.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0d1f15d6ba9959164008d2b5e17ed3d"><gtr:id>b0d1f15d6ba9959164008d2b5e17ed3d</gtr:id><gtr:otherNames>Usuf E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>5a93eea13cdc29.23636767</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_MR/J010391/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>